^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | luminespib (AUY922) (HSP90 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
AUY922 in Patient With Stage IV NSCLC
Excerpt:
...To define the by RECIST 1.1 of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC`Objective response rate...
Trial ID:
Source:
Title:
Pemetrexed Disodium and Hsp90 Inhibitor AUY922 in Treating Patients With Previously Treated Stage IV Non-Small Cell Lung Cancer
Excerpt:
...5 participants with anaplastic lymphoma receptor tyrosine kinase (ALK) gene rearrangement, 5 participants with wild type v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS), EGFR and ALK)...
Trial ID:
Less C2 evidence
Source:
Title:
Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer
Excerpt:
In this phase 2 study, we evaluated the activity of AUY922 in pretreated patients with stage IV NSCLC….Patients with advanced NSCLC were divided into molecularly defined strata based on mutations in the EGFR gene, the ALK receptor tyrosine kinase gene (ALK), the KRAS gene, or the wild type of all three....Biomarker data showed activity of AUY922 in EGFR-mutant patients with exon 19 deletion, T790M mutation, and exon 20 insertion....AUY922 is active in patients with NSCLC, particularly among patients with ALK rearrangements and EGFR mutations.
DOI:
https://doi.org/10.1016/j.jtho.2017.11.131
Trial ID:
